Alterity Therapeutics Ltd (ATHE NASDAQ) stock market data APIs
$4.4899
0.4(8.9%)
as of May 4, 2026
Try our APIs with
free plan!
Alterity Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Prev. Close
4.4899
Open
4.8911
High
4.9276
Low
4.4845
52 wk Range
2.66-7
Market Cap
85 469 K
Shares Outstanding
18 126 K
Revenue
6 636 K
EPS
0
Beta
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alterity Therapeutics Ltd data using free add-ons & libraries
Get Alterity Therapeutics Ltd Fundamental Data
Alterity Therapeutics Ltd Fundamental data includes:
- Net Revenue: 6 636 K
- EBITDA: -17 550 620
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Alterity Therapeutics Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-28
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alterity Therapeutics Ltd News
New
Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 progra...
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
ALTERITY THERAPEUTICS LIMITED MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotec...
Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial
(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its p...
Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor
(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026. Claassen is Professor of Neurology at Vanderbi...
Get Alterity Therapeutics Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
